Journal article
Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma
Immunotherapy, Vol.10(7), pp.595-604
03/01/2018
DOI: 10.2217/imt-2017-0142
PMCID: PMC6367711
PMID: 29569508
Abstract
Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.
Details
- Title: Subtitle
- Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma
- Creators
- Brittany E GivensSean M GearyAliasger K Salem
- Resource Type
- Journal article
- Publication Details
- Immunotherapy, Vol.10(7), pp.595-604
- DOI
- 10.2217/imt-2017-0142
- PMID
- 29569508
- PMCID
- PMC6367711
- NLM abbreviation
- Immunotherapy
- ISSN
- 1750-743X
- eISSN
- 1750-7448
- Publisher
- Future Medicine Ltd
- Language
- English
- Date published
- 03/01/2018
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Dental Research; Chemical and Biochemical Engineering
- Record Identifier
- 9983985930802771
Metrics
20 Record Views